תבנית:תרופה/סימבקור 10 - Simvacor 10: הבדלים בין גרסאות

|במרשם=כן

|במרשם=כן

|התוויה={{{התוויה|<div style="direction:ltr;">Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvacor is indicated to: Reduce the risk of total mortality by reducing coronary death Reduce the risk of non-fatal myocardial infarction Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvacor is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvacor therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvacor is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).</div>}}}

|התוויה={{{התוויה|<div style="direction:ltr;">Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvacor is indicated to: Reduce the risk of total mortality by reducing coronary death Reduce the risk of non-fatal myocardial infarction Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvacor is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvacor therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvacor is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).</div>}}}

|התוויות נגד=

|התוויות נגד=

|פרמקודינמיקה={{{פרמקודינמיקה|}}}

|פרמקודינמיקה={{{פרמקודינמיקה|}}}